TABLE OF CONTENTS
Volume 1, Issue 3 (April 2004)
Top of page
Top of page
Top of page
Top of page
Editorial
Top of pagePapers
TRIPS-plus provisions in trade agreements and their potential adverse effects on public health
María Fabiana Jorge
J Generic Med 1: 199-211; doi:10.1057/palgrave.jgm.4940023
US generic drug litigation update
Eric B Fastiff
J Generic Med 1: 212-218; doi:10.1057/palgrave.jgm.4940024
Orange Book patent listing: The rationale and economic impact of the new rule
Mark Pohl
J Generic Med 1: 219-227; doi:10.1057/palgrave.jgm.4940025
Pharmaceutical pricing and Hatch–Waxman reform: The right prescription
Allison K Young and Meredyth Smith Andrus
J Generic Med 1: 228-237; doi:10.1057/palgrave.jgm.4940026
'Is marketed' — The story and the ECJ Decision. The case of Generics [UK]
Howard Rosenberg
J Generic Med 1: 238-241; doi:10.1057/palgrave.jgm.4940027
Optimising supply chain investments — An integrated approach
Jo Pisani
J Generic Med 1: 242-248; doi:10.1057/palgrave.jgm.4940028
Innovation — Patents, generics and payers: The political dynamics of interaction
Heinz Redwood
J Generic Med 1: 249-258; doi:10.1057/palgrave.jgm.4940029
Are biopharmaceuticals immune to the generics threat?
Enrico T Polastro and Sonia Tulcinsky
J Generic Med 1: 259-265; doi:10.1057/palgrave.jgm.4940030
US Legal and Regulatory Update
New Medicare law brings changes to Hatch–Waxman Act
J Generic Med 1: 267-272; doi:10.1057/palgrave.jgm.4940031
Patent Expiry Impact Predictor
Blockbuster product patent expiry
J Generic Med 1: 273-280; doi:10.1057/palgrave.jgm.4940032
